JOURNEY MEDICAL CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.7 USD | +0.43% |
|
+20.51% | -18.40% |
| May. 13 | Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024 | |
| May. 13 | Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 89.63 | 34.11 | 106.6 | 93.66 | - | - |
| Enterprise Value (EV) 1 | 89.63 | 34.11 | 106.6 | 93.66 | 93.66 | 93.66 |
| P/E ratio | -1.25 x | -1.14 x | -27.4 x | -5.03 x | -19.6 x | -19.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.42 x | 0.46 x | 1.35 x | 1.65 x | 1.17 x | 1.23 x |
| EV / Revenue | 1.42 x | 0.46 x | 1.35 x | 1.65 x | 1.17 x | 1.23 x |
| EV / EBITDA | -3 x | -4.68 x | 6.84 x | 24.5 x | 4.71 x | - |
| EV / FCF | -41,095,321 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,660 | 17,766 | 18,508 | 20,013 | - | - |
| Reference price 2 | 5.380 | 1.920 | 5.760 | 4.700 | 4.700 | 4.700 |
| Announcement Date | 3/28/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 63.13 | 73.67 | 79.18 | 56.82 | 80.37 | 76.46 |
| EBITDA 1 | - | -29.84 | -7.283 | 15.59 | 3.828 | 19.9 | - |
| EBIT 1 | - | -34.88 | -27.52 | -2.073 | -17.51 | -13.25 | -4.337 |
| Operating Margin | - | -55.25% | -37.35% | -2.62% | -30.81% | -16.48% | -5.67% |
| Earnings before Tax (EBT) 1 | - | -42.36 | -29.56 | -3.632 | -17.91 | -4.174 | -5.152 |
| Net income 1 | 5.283 | -43.99 | -29.63 | -3.853 | -17.91 | -4.616 | -5.152 |
| Net margin | - | -69.68% | -40.22% | -4.87% | -31.51% | -5.74% | -6.74% |
| EPS 2 | 0.4900 | -4.320 | -1.690 | -0.2100 | -0.9350 | -0.2400 | -0.2400 |
| Free Cash Flow | - | -2.181 | - | - | - | - | - |
| FCF margin | - | -3.45% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 7/22/21 | 3/28/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.52 | 23.3 | 18.29 | 16.12 | 15.97 | 12.21 | 17.17 | 34.54 | 15.26 | 13.03 | 13.65 | 14.54 | 14.66 |
| EBITDA 1 | -4.708 | 2.308 | -2.571 | -4.019 | -3.001 | -5.86 | -0.639 | 20.82 | 0.724 | 0.011 | 0.805 | 1.475 | 1.538 |
| EBIT 1 | -9.057 | -0.888 | -7.142 | -9.492 | -9.995 | -9.561 | -7.653 | 17.24 | -2.104 | -10.09 | -2.724 | -3.207 | -3.368 |
| Operating Margin | -51.7% | -3.81% | -39.05% | -58.9% | -62.6% | -78.29% | -44.57% | 49.93% | -13.79% | -77.44% | -19.96% | -22.06% | -22.97% |
| Earnings before Tax (EBT) 1 | -13.42 | -1.274 | -7.592 | -10.07 | -10.63 | -10.14 | -8.363 | 16.88 | -2.017 | -10.44 | -2.942 | -2.716 | -2.757 |
| Net income 1 | -21.75 | -1.378 | -7.528 | -10.08 | -10.64 | -10.14 | -8.363 | 16.79 | -2.143 | -10.44 | -2.942 | -2.716 | -2.757 |
| Net margin | -124.17% | -5.92% | -41.16% | -62.55% | -66.65% | -82.99% | -48.7% | 48.61% | -14.05% | -80.14% | -21.56% | -18.68% | -18.8% |
| EPS 2 | -1.890 | -0.0800 | -0.4300 | -0.5700 | -0.6000 | -0.5700 | -0.4600 | 0.8000 | -0.1200 | -0.5300 | -0.1550 | -0.1450 | -0.1450 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/10/22 | 8/9/22 | 11/10/22 | 3/29/23 | 5/22/23 | 8/8/23 | 11/7/23 | 3/21/24 | 5/13/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -2.18 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 7/22/21 | 3/28/22 | 3/29/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.7
USD
Average target price
8.25
USD
Spread / Average Target
+75.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.40% | 93.66M | |
| +45.82% | 754B | |
| +40.95% | 630B | |
| -6.16% | 352B | |
| +19.86% | 331B | |
| +9.32% | 298B | |
| +18.45% | 250B | |
| +11.88% | 217B | |
| -0.78% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- DERM Stock
- Financials Journey Medical Corporation
